Alembic believes that Research & Development is the growth engine for its foray into the regulated and semi regulated markets. All R&D initiatives are guided by the organizational philosophy of providing affordable yet high quality medicines for health care and wellness.
Alembic has state of art R&D Centres at Baroda and Hyderabad with more than 500 Scientists working on Active Pharmaceutical ingredients (APIs), Oral Solid Dosage forms, trans Dermal, Injectable etc.
Alembic Research Centre at Vadodara is focused on novel chemistry including new polymorphs, salts, process for a possible first to file opportunity. The fully integrated R&D is enabled by AR&D, IP, RA, QA, Technology transfer teams and USFDA inspected pilot plants.
At AG Research, Alembic’s R&D unit in Hyderabad, there are 3 major functions, viz.:- Formulation Development, Analytical Development & Peptide (API) Lab Development with a team of around 50 scientists. All developmental activities are conducted as per global regulatory guidelines through in-house quality controlled designs using QbD & DOE concepts. The Intellectual Property Portfolios are being created for differentiated & innovative ideas.
Alembic’s Bioequivalence Centre, located in Vadodara offers BA/BE services to support R&D. It has been operational since 2004. Positioned adjacent to Bhailal Amin General Hospital, one of the largest tertiary care hospital in Vadodara, it has a state-of-the-art facility which spreads over 33000 sq ft. There are more than 120 scientists for BA/BE studies. The centre is inspected by USFDA, BfArM (Germany), MPA (Sweden), ANVISA (Brazil), MoH (Turkey) and DCGI (CDSCO) and conforms to every stringent industry prerequisite.